$ 85 / 16mg
999 in stock (can be backordered)
ARA-290 (Cibinetide) is an 11-amino-acid synthetic peptide derived from erythropoietin (EPO) that selectively targets the innate repair receptor (IRR) without activating the classical erythropoietin receptor responsible for red blood cell production.
This receptor selectivity makes ARA-290 a uniquely valuable research tool for studying tissue-protective, anti-inflammatory, and neuroprotective pathways independent of erythropoiesis — an important distinction for researchers who need to isolate repair signaling from hematopoietic effects.
ARA-290 activates the innate repair receptor (IRR), a heterodimer composed of the EPO receptor subunit and the beta common receptor (βcR). Unlike full-length erythropoietin, which primarily drives red blood cell production through the homodimeric EPOR, ARA-290 does not stimulate erythropoiesis at any tested concentration.
Instead, its activation of the IRR triggers a distinct signaling cascade that has been studied for tissue-protective and anti-inflammatory effects across multiple organ systems.
In preclinical models, IRR activation by ARA-290 has been associated with reduced neuroinflammation through suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), promotion of Schwann cell survival and nerve regeneration, and modulation of metabolic stress responses including improved insulin sensitivity.
These effects have been documented in published research including studies by Brines et al. (2014) in Molecular Medicine, which characterized the IRR signaling pathway and ARA-290’s selective receptor pharmacology.
ARA-290 has been extensively studied in neuropathy models, where IRR activation promotes Schwann cell survival and supports nerve-fiber regeneration. Clinical research has examined its effects on small-fiber neuropathy, corneal nerve density, and neuropathic pain — areas where tissue-protective signaling without erythropoietic side effects is critical for experimental design.
The IRR pathway activated by ARA-290 modulates NF-κB signaling and reduces pro-inflammatory cytokine expression. This makes it useful in research models examining chronic inflammation, tissue injury, and repair processes where inflammatory resolution — rather than immune suppression — is the desired experimental outcome.
Preclinical research has explored this compound for its effects on metabolic stress responses, including improved glucose handling and insulin-receptor signaling. These metabolic studies complement its neuroprotective profile, as metabolic dysfunction and neuroinflammation often co-occur in research models of diabetic neuropathy and metabolic syndrome.
This peptide has been studied in corneal-nerve regeneration models, where it promotes nerve-fiber density recovery following injury or surgical disruption. This application takes advantage of the cornea’s accessibility for imaging and quantification, providing a well-characterized model system for studying nerve-repair mechanisms.
Researchers studying neuroprotective and anti-inflammatory pathways often explore Cibinetide alongside complementary peptides that target tissue repair through different mechanisms:
Each vial contains 16 mg of ARA-290 research peptide manufactured in the USA under ISO-certified conditions. Every batch is verified to ≥99% purity by HPLC analysis, screened for endotoxin levels below 0.1 EU/mg, and supplied with a full Certificate of Analysis (COA) available upon request. Shipped lyophilized for maximum stability. Store at 2–8°C upon receipt. For laboratory research use only — not for human consumption.
In preclinical and clinical research settings, this peptide (Cibinetide) is primarily studied for its neuroprotective, anti-inflammatory, and tissue-repair properties. Key research areas include small-fiber neuropathy, corneal nerve regeneration, chronic inflammation, and metabolic stress responses. It activates the innate repair receptor without stimulating red blood cell production, making Cibinetide a selective tool for studying tissue-protective pathways.
While both interact with EPO receptor subunits, they activate different receptor complexes. Full-length EPO primarily stimulates the homodimeric EPOR to drive red blood cell production. In contrast, Cibinetide selectively activates the innate repair receptor (IRR) — a heterodimer of the EPOR and beta common receptor — triggering tissue-protective signaling without erythropoietic effects.
Each 16 mg vial is manufactured in the USA under ISO-certified conditions, verified to ≥99% purity by HPLC analysis, and screened for endotoxin levels below 0.1 EU/mg. A full Certificate of Analysis (COA) is available upon request. The product ships lyophilized and should be stored at 2–8°C upon receipt.
